Utility of genomic sequencing classifier in managing cytologically indeterminate oncocytic thyroid nodules
Afirma GSC has a high BCR and improved performance over earlier generation molecular tests in oncocytic thyroid nodules, particularly for Bethesda IV. However, the PPV in Bethesda III nodules remains low, especially in the presence of Hashimoto's thyroiditis.
Authors
- Benjamin Altshuler
- Masha J. Livhits (ORCID: https://orcid.org/0000-0002-8436-392X)
- Athanasios Bikas (ORCID: https://orcid.org/0000-0001-6362-3772)
- Anupam Kotwal (ORCID: https://orcid.org/0000-0002-4500-8546)
- Sara Ahmadi
- Michael W. Yeh
- Anery Patel
- Gunjan Arora
- Jetesh Sahadeo
- Elena G Hughes
Institutions
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1210/clinem/dgag044
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 30.73